ORIX Life Begins Offering Cancer Insurance “Wish” That Can Support Wider Cancer Treatment Options with a Sizeable Lump-Sum Benefit

TOKYO, Japan - February 26, 2021 - ORIX Life Insurance Corporation (“ORIX Life”) announced today that it will commence offering the cancer insurance “Wish” from April 2, 2021.

“Wish” is a term insurance for cancer that offers a lump-sum benefit as high as six million yen. Amid the diversification of treatment for cancer, this insurance allows patients to choose the most appropriate treatment methods from the wide range of options through receiving a sizeable lump-sum benefit during cancer diagnosis. In addition, to allow patients to focus on treatment during critical life stages that cannot be lost to cancer, such as during one’s working life, it was made a term insurance so that ample security can be put in place at affordable insurance premiums.

Research and development into cancer treatments is always evolving, and treatment options have increased. However, there may be cases when a patient’s desired treatment falls under categories such as advanced medical treatment or optional treatment, resulting in a large amount of out-of-pocket expense. In addition to higher expenses such as treatment fees, patients may also suffer a reduction in income when affected by cancer owing to changes in working styles. This can impact other aspects of a patient’s life, such as the livelihood of one’s family or children’s schooling. This insurance was developed for the purpose of preparing for such risks by guaranteeing a sizeable lump-sum benefit when one is diagnosed with cancer.

Going forward, ORIX Life will continue to provide offerings that meet the needs of the times, and will strive to continue to be an insurance company chosen by many customers.

^* Together with the launch of this insurance, the cancer insurance “Force” will no longer be offered as of April 1, 2021.

• A lump-sum cancer benefit (one million yen) can be received any number of times when first diagnosed with cancer or when hospitalization commences for the purpose of cancer treatment. ^* Limited to once per year
• A lump-sum cancerous tumor first-time diagnosis benefit (up to five million yen) can be received when first diagnosed
• “Wish” was made a term insurance so that ample security can be put in place at affordable insurance premiums allowing patients to focus on treatment
• Concerns are addressed through a health and treatment consultation service, including second opinions

* Coverage for cancer and cancerous tumors commences on the 91st day from the effective date of policy, including the effective date itself.
* The lump-sum benefit that can be selected differs according to the insured person’s age.
* Intraepithelial neoplasms (IEN) and skin cancers (excluding malignant melanoma) are not included in coverage for cancerous tumors.

Contact Information:
Investor Relations and Sustainability Department
ORIX Corporation
Tel: +81-3-3435-3121

About ORIX:
ORIX Corporation (TSE: 8591; NYSE: IX) is a financial services group which provides innovative products and services to its customers by constantly pursuing new businesses.
Established in 1964, from its start in the leasing business, ORIX has advanced into neighboring fields and at present has expanded into lending, investment, life insurance, banking, asset management, automobile related, real estate and environment and energy related businesses. Since entering Hong Kong in 1971, ORIX has spread its businesses globally by establishing locations in 34 countries and regions across the world.
Going forward, ORIX intends to utilize its strengths and expertise, which generate new value, to establish an independent ORIX business model that continues to evolve perpetually. In this way, ORIX will engage in business activities that instill vitality in its companies and workforce, and thereby contribute to society. For more details, please visit our website: https://www.orix.co.jp/grp/en/
(As of September 30, 2020)

Caution Concerning Forward Looking Statements:
These documents May contain forward-looking statements about expected future events and financial results that involve risks and uncertainties. Such statements are based on our current expectations and are subject to uncertainties and risks that could cause actual results that differ materially from those described in the forward-looking statements. Factors that could cause such a difference include, but are not limited to, those described under “Risk Factors” in the Company’s annual report on Form 20-F filed with the United States Securities and Exchange Commission and under “(4) Risk Factors” of the “1. Summary of Consolidated Financial Results” of the “Consolidated Financial Results April 1, 2019 – March 31, 2020.”